Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Genovate Biotechnology Co's Revenue for the
three
months ended in Mar. 2026 was NT$110.4 Mil. Genovate Biotechnology Co's average Accounts Receivable for the
three
months ended in Mar. 2026 was NT$70.4 Mil.
Hence, Genovate Biotechnology Co's Receivables Turnover for the
three
months ended in Mar. 2026 was 1.57.
Genovate Biotechnology Co (ROCO:4130) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Genovate Biotechnology Co Receivables Turnover Related Terms
Genovate Biotechnology Co Receivables Turnover Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genovate Biotechnology Co Receivables Turnover Chart
ROCO:4130 vs VRTX, REGN, RVMD: Receivables Turnover Comparison
For the Biotechnology subindustry, Genovate Biotechnology Co's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genovate Biotechnology Co Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genovate Biotechnology Co's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Genovate Biotechnology Co's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genovate Biotechnology Co (ROCO:4130) has a Receivables Turnover of 1.57 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Genovate Biotechnology Co and its competitors. According to the industry distribution chart, Genovate Biotechnology Co ranks #358 out of 841 companies in the Biotechnology industry, placing it in the top 42.6%.
Is Genovate Biotechnology Co's Receivables Turnover too high?
Genovate Biotechnology Co's current Receivables Turnover is 1.57. The Biotechnology industry median Receivables Turnover is 5.27. Genovate Biotechnology Co's value of 1.57 is 70.2% below this industry median. Based on the distribution chart, Genovate Biotechnology Co ranks #358 out of 841 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Genovate Biotechnology Co has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Genovate Biotechnology Co's Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genovate Biotechnology Co ranks #358 out of 841 companies for Receivables Turnover. This puts Genovate Biotechnology Co in the upper half of its industry. The industry median Receivables Turnover is 5.27. Genovate Biotechnology Co's value of 1.57 is 70.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.27, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genovate Biotechnology Co's current Receivables Turnover of 1.57 is 70.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Genovate Biotechnology Co and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genovate Biotechnology Co's current Receivables Turnover is 1.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genovate Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, Genovate Biotechnology Co (ROCO:4130) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$20.00, compared to a current price of NT$26.70 — trading 33.5% above its estimated fair value. The current Receivables Turnover is 1.57 and 70.2% below the Biotechnology industry median of 5.27. Genovate Biotechnology Co's overall GF Score™ is 50/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Genovate Biotechnology Co (ROCO:4130), the current Receivables Turnover is 1.57 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genovate Biotechnology Co (ROCO:4130) Overvalued in 2026?
Based on GuruFocus' analysis, Genovate Biotechnology Co stock appears to be overvalued.
The current stock price of NT$26.70 is trading 33.5% above its estimated GF Value™ of NT$20.00.
GuruFocus considers Genovate Biotechnology Co to be Significantly Overvalued.
Key valuation signals for ROCO:4130:
Receivables Turnover: 1.57
GF Value™: NT$20.00 vs. price of NT$26.70 (33.5% above fair value)
Industry Position: 70.2% below the Biotechnology median (#358 of 841)
No single metric tells the full story. See the ROCO:4130 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genovate Biotechnology Co Ltd develops, produces, manufactures, and sales of medicines for the prevention and treatment of diseases caused by viruses and bacteria, and medicines for the treatment of cardiovascular, gastrointestinal, cancer, and autoimmune diseases, etc. The company is also engaged in the sales of medicines for the prevention and treatment of diseases caused by viruses and bacteria, and medicines for the treatment of cardiovascular, gastrointestinal, cancer, and autoimmune diseases etc.
50GF Score
Get the complete analysis for ROCO:4130
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4130 has been successfully added to your 
